SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...

As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

Mineralys Therapeutics Inc (MLYS) showcases promising trial results and strategic initiatives amid financial challenges and competitive pressures.

Levy reported R&D expenses of $38.3 million for Q2 2025, down from $39.3 million in the prior year period, attributed to the conclusion of the lorundrostat pivotal program, partially offset by ...

A newer type of diabetes medication called sodium-glucose cotransporter-2 (SGLT2) inhibitors has been linked to a rare but ...

There is lower risk for recurrent HF hospitalization in older patients that receive SGLT2is following acute decompensated heart failure.

Q: I have Type 2 diabetes, and my doctor insists that I give up beverages with almost all sugar substitutes and stick with water. Can you explain what’s wrong with ...